Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

2.

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.

J Natl Cancer Inst. 2014 Aug 5;106(9). pii: dju215. doi: 10.1093/jnci/dju215. Print 2014 Sep.

3.

AXL mediates resistance to cetuximab therapy.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL.

Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18.

4.

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.

Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.

5.

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.

Br J Cancer. 2014 Jun 10;110(12):2887-95. doi: 10.1038/bjc.2014.241. Epub 2014 May 13.

6.

PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.

Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.

Clin Cancer Res. 2013 Jul 15;19(14):3808-19. doi: 10.1158/1078-0432.CCR-12-2716. Epub 2013 May 2.

7.

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.

Sen T, Tong P, Diao L, Li L, Fan Y, Hoff J, Heymach JV, Wang J, Byers LA.

Clin Cancer Res. 2017 Oct 15;23(20):6239-6253. doi: 10.1158/1078-0432.CCR-17-1284. Epub 2017 Jul 11.

8.

Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Leiker AJ, DeGraff W, Choudhuri R, Sowers AL, Thetford A, Cook JA, Van Waes C, Mitchell JB.

Clin Cancer Res. 2015 Jun 15;21(12):2792-801. doi: 10.1158/1078-0432.CCR-14-3279. Epub 2015 Feb 27.

9.

MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.

Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, Park BM, Park E, Bae JH, Choi CM, Lee JC.

Cancer Res. 2014 Jan 1;74(1):253-62. doi: 10.1158/0008-5472.CAN-13-1103. Epub 2013 Oct 28.

10.
11.

Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma.

Paccez JD, Duncan K, Vava A, Correa RG, Libermann TA, Parker MI, Zerbini LF.

Mol Biol Cell. 2015 Mar 1;26(5):821-31. doi: 10.1091/mbc.E14-04-0868. Epub 2015 Jan 7.

12.

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.

Mizrachi A, Shamay Y, Shah J, Brook S, Soong J, Rajasekhar VK, Humm JL, Healey JH, Powell SN, Baselga J, Heller DA, Haimovitz-Friedman A, Scaltriti M.

Nat Commun. 2017 Feb 13;8:14292. doi: 10.1038/ncomms14292.

13.

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.

Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.

Mol Cancer Ther. 2013 Nov;12(11):2541-58. doi: 10.1158/1535-7163.MCT-13-0170. Epub 2013 Sep 11.

14.

A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM.

Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.

15.

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY.

Mol Cancer Ther. 2011 Dec;10(12):2437-48. doi: 10.1158/1535-7163.MCT-11-0235. Epub 2011 Oct 6.

16.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

17.

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6099.

18.
19.

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Scaltriti M, Elkabets M, Baselga J.

Clin Cancer Res. 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR-15-1458. Epub 2016 Jan 13. Review.

20.

ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, Kim HR, Hong MH, Yoon SO, Cho BC.

Oncogene. 2018 Jan 18;37(3):377-388. doi: 10.1038/onc.2017.339. Epub 2017 Sep 25.

PMID:
28945228

Supplemental Content

Support Center